https://www.selleckchem.com/pr....oducts/proxalutamide
9% vs. 6.5%, P less then 0.001; median OS not reached vs. 9.6 months, log-rank P less then 0.001; median PFS 9.6 vs. 2.8 months, log-rank P less then 0.001). In multivariate analysis, AFP response was an independent factor associated with good OS (hazard ratio [HR]=0.301, P=0.001) and PFS (HR=0.332, P less then 0.001). Moreover, AFP responders had higher ORR and better OS as well as PFS than non-responders, regardless of nivolumab as a first- or more than a second-line therapy (all P less then 0.05). In conclusion, the nove
Like
Comment
Share
